Abstract:Although previous studies have focused on hepatobiliary and gastrointestinal adverse drug reactions (ADRs) associated with COVID‐19 vaccines, literature on such ADRs with other vaccines is limited, particularly on a global scale. Therefore, we aimed to investigate the global burden of vaccine‐associated hepatobiliary and gastrointestinal ADRs and identify the vaccines implicated in these occurrences. This study utilized data from the World Health Organization (WHO) international pharmacovigilance database to extract reports of vaccine‐associated hepatobiliary and gastrointestinal ADRs from 1967 to 2023 (total reports = 131 255 418). Through global reporting counts, reported odds ratios (ROR) with 95% confidence interval (CI), and information components (IC) with IC0.25, the study examined the association between 16 vaccines and the incidence of hepatobiliary and gastrointestinal ADRs across 156 countries. Of the 6 842 303 reports in the vaccine‐associated ADRs, 10 786 reports of liver injury, 927 870 reports of gastrointestinal symptoms, 2978 reports of pancreas and bile duct injury, and 96 reports of intra‐abdominal hemorrhage between 1967 and 2023 were identified. Most hepatobiliary and gastrointestinal ADRs surged after 2020, with the majority of reports attributed to COVID‐19 messenger RNA (mRNA) vaccines. Hepatitis A vaccines exhibited the highest association with liver injury (ROR [95% CI]: 10.30 [9.65–10.99]; IC [IC0.25]: 3.33 [3.22]), followed by hepatitis B, typhoid, and rotavirus. Specifically, ischemic hepatitis had a significant association with both Ad5‐vectored and mRNA COVID‐19 vaccines. Gastrointestinal symptoms were associated with all vaccines except for tuberculosis vaccines, particularly with rotavirus (11.62 [11.45–11.80]; 3.05 [3.03]) and typhoid (11.02 [10.66–11.39]; 3.00 [2.96]). Pancreas and bile duct injury were associated with COVID‐19 mRNA (1.99 [1.89–2.09]; 0.90 [0.83]), MMR (measles, mumps, and rubella), and papillomavirus vaccines. For intra‐abdominal hemorrhage, inactivated whole‐virus COVID‐19 vaccines (3.93 [1.86–8.27]; 1.71 [0.41]) had the highest association, followed by COVID‐19 mRNA (1.81 [1.42–2.29]; 0.77 [0.39]). Most of these ADRs had a short time to onset, within 1 day, and low mortality rate. Through a global scale database, the majority of ADRs occurred within 1 day, emphasizing the importance of healthcare workers' vigilant monitoring and timely management.

Inspiration to Mrna-Based COVID-19 Vaccination: Serious Adverse Case Reports with Hepatitis B Vaccine in Real-World

Acute hepatitis following mRNA BNT162b2 COVID-19 vaccination

Analysis on 124 Cases Of(suspected)adverse Events Following Immunization of Hepatitis B Vaccine Reported in Documents

Analysis of deaths following yeast-derived hepatitis B vaccination of infants, China, January 2013 to December 2020

Media and Public Reactions Toward Vaccination During the 'hepatitis B Vaccine Crisis' in China.

An overview and single-arm meta-analysis of immune-mediated adverse events following COVID-19 vaccination

A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China.

Adverse event reporting following immunization of hepatitis B vaccine: A 13-year review

Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines

Safety and antibody response to inactivated COVID‐19 vaccine in patients with chronic hepatitis B virus infection

A comprehensive analysis of the efficacy and safety of COVID-19 vaccines.

Suitable hepatitis B vaccine for adult immunization in China: a systematic review and meta-analysis.

Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period.

Suggestions to the Hepatitis B Vaccine Events

Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China

Global burden of vaccine‐associated hepatobiliary and gastrointestinal adverse drug reactions, 1967–2023: A comprehensive analysis of the international pharmacovigilance database

Prospective clinical trial of hepatitis B vaccination for children with hematological malignancies: a study on the safety and immunogenicity efficacy

Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer–based COVID-19 vaccine ZF2001 in chronic hepatitis B patients

Risk of myocarditis after three doses of COVID‐19 mRNA vaccines in the United States, 2020–2022: A self‐controlled case series study